Market overview
The global dental oral microbiome market is worth USD 255 mn in 2026 and is forecast to reach USD 662 mn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Oral probiotic lozenges and tablets is the largest by product segment.
| Scope | Oral probiotics, prebiotics and microbiome tests marketed for dental and gum health, sold as lozenges, powders and laboratory test kits. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 230 mn |
| Value 2026 | USD 255 mn |
| Value 2036 | USD 662 mn |
| CAGR 2026-2036 | 10.0% |
| Volume 2026 | 105 million units |
| Volume 2036 | 259 million units |
| Average price 2026 | USD 2.43 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Dental Oral Microbiome market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 255 mn |
| 2027 | USD 281 mn |
| 2028 | USD 309 mn |
| 2029 | USD 340 mn |
| 2030 | USD 374 mn |
| 2031 | USD 411 mn |
| 2032 | USD 452 mn |
| 2033 | USD 498 mn |
| 2034 | USD 547 mn |
| 2035 | USD 602 mn |
| 2036 | USD 662 mn |
Dental Oral Microbiome market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral probiotic lozenges and tablets | 58.0% | 55.5% | USD 148 mn | 9.5% |
| Prebiotic and microbiome-support products | 24.0% | 21.9% | USD 61 mn | 9.0% |
| Oral microbiome tests | 18.0% | 22.5% | USD 46 mn | 12.5% |
By channel
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharmacies and retail | 46.0% | 41.5% | USD 117 mn | 8.9% |
| Online | 32.0% | 37.8% | USD 82 mn | 11.8% |
| Dental clinics | 22.0% | 20.8% | USD 56 mn | 9.4% |
By application
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Probiotics | 38.0% | 38.0% | USD 97 mn | 10.0% |
| Diagnostic testing | 24.0% | 26.0% | USD 61 mn | 10.9% |
| Oral care formulations | 30.0% | 28.0% | USD 77 mn | 9.2% |
| Research kits | 8.0% | 8.0% | USD 20 mn | 10.0% |
By consumer type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Adults | 58.0% | 56.0% | USD 148 mn | 9.6% |
| Seniors | 22.0% | 24.0% | USD 56 mn | 11.0% |
| Children | 20.0% | 20.0% | USD 51 mn | 10.0% |
By format
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Toothpastes and rinses | 36.0% | 33.0% | USD 92 mn | 9.1% |
| Lozenges and chewables | 28.0% | 28.0% | USD 71 mn | 10.0% |
| Test kits | 18.0% | 20.0% | USD 46 mn | 11.2% |
| Others formats | 18.0% | 19.0% | USD 46 mn | 10.6% |
Top 25 countries for dental oral microbiome by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.0% of 2026 revenue and the 25 countries below together hold 97.0%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 77 mn | 30.0% | USD 194 mn | 9.7% |
| 2 | Japan | USD 31 mn | 12.0% | USD 74 mn | 9.2% |
| 3 | China | USD 26 mn | 10.0% | USD 85 mn | 12.8% |
| 4 | Germany | USD 20 mn | 8.0% | USD 47 mn | 8.7% |
| 5 | South Korea | USD 15 mn | 6.0% | USD 46 mn | 11.7% |
| 6 | United Kingdom | USD 15 mn | 6.0% | USD 37 mn | 9.2% |
| 7 | Italy | USD 13 mn | 5.0% | USD 30 mn | 8.8% |
| 8 | France | USD 10 mn | 4.0% | USD 24 mn | 8.8% |
| 9 | Brazil | USD 10 mn | 4.0% | USD 28 mn | 10.8% |
| 10 | Australia | USD 10 mn | 4.0% | USD 27 mn | 10.3% |
| 11 | Netherlands | USD 2.6 mn | 1.0% | USD 6.4 mn | 9.3% |
| 12 | Spain | USD 2.1 mn | 0.8% | USD 5.2 mn | 9.3% |
| 13 | Switzerland | USD 2.0 mn | 0.8% | USD 4.8 mn | 9.3% |
| 14 | Canada | USD 1.9 mn | 0.8% | USD 4.6 mn | 9.2% |
| 15 | India | USD 1.9 mn | 0.7% | USD 5.2 mn | 10.6% |
| 16 | Mexico | USD 1.7 mn | 0.7% | USD 4.6 mn | 10.5% |
| 17 | Sweden | USD 1.5 mn | 0.6% | USD 3.7 mn | 9.4% |
| 18 | Belgium | USD 1.4 mn | 0.5% | USD 3.3 mn | 9.4% |
| 19 | Russia | USD 1.0 mn | 0.4% | USD 2.8 mn | 10.5% |
| 20 | Taiwan | USD 1.00 mn | 0.4% | USD 2.7 mn | 10.6% |
| 21 | Turkey | USD 0.82 mn | 0.3% | USD 2.2 mn | 10.7% |
| 22 | Thailand | USD 0.79 mn | 0.3% | USD 2.1 mn | 10.3% |
| 23 | Poland | USD 0.64 mn | 0.2% | USD 1.8 mn | 10.8% |
| 24 | Austria | USD 0.61 mn | 0.2% | USD 1.5 mn | 9.5% |
| 25 | Saudi Arabia | USD 0.51 mn | 0.2% | USD 1.4 mn | 10.5% |
| Rest of world | USD 7.6 mn | 3.0% | USD 17 mn | 8.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- BioGaia
- Colgate-Palmolive
- Haleon
- Sunstar
Group 2: Regional and specialist players
- BLIS Technologies
- ProBiora Health
- Church and Dwight
- Lion Corporation
- Morinaga Milk
- Dentaid
- OralDNA Labs
Group 3: Emerging and niche players
- Hyperbiotics
- Oral Genome
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the dental oral microbiome market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.0% is calculated from the resulting values.
The market is divided by product, by channel, by application, by consumer type, by format. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the dental oral microbiome market?
The global dental oral microbiome market is estimated at USD 230 mn in 2025 and USD 255 mn in 2026.
How fast will the dental oral microbiome market grow?
It is forecast to reach USD 662 mn by 2036, a compound annual growth rate of 10.0% from 2026, an increase of USD 407 mn.
Which country is the largest market for dental oral microbiome?
United States is the largest market by revenue at USD 77 mn in 2026, 30.0% of the global total. The three largest countries together hold 52.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 12.8% a year from 2026 to 2036.
Which dental oral microbiome segment is largest?
In the by product split, Oral probiotic lozenges and tablets is the largest segment with 58.0% of 2026 revenue.
Who are the leading dental oral microbiome companies?
Global leaders include BioGaia, Colgate-Palmolive, Haleon, Sunstar.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Automated CPR DeviceUSD 253 mn · 5.5% CAGR
- HIV Self-testingUSD 259 mn · 7.5% CAGR
- Augmented Glenoid SystemsUSD 251 mn · 8.5% CAGR
- Synthetic Clinical Trial DataUSD 260 mn · 22.0% CAGR
- Dengue VaccinesUSD 247 mn · 22.0% CAGR
- Medical Device Cyber Risk QuantificationUSD 244 mn · 15.0% CAGR
- Continuous Peripheral Nerve Block CatheterUSD 243 mn · 5.0% CAGR
- Diagnostic Exosome BiomarkersUSD 242 mn · 15.0% CAGR